 He is a member of The Adverse Drug Committee of the Norwegian Medical Agency.Reikvam is a Fellow of the European Society of Cardiology (FESC) and a member of the Working Group of Cardiovascular Pharmacology and Drug Therapy of the society.He has been a member of EMEA's (European Medicines Agency) pharmacovigilance working party and has had health care evaluation assignments for OECD.